Ekaterina Vert-Wong | Vice President, Portfolio & Alliance Management
Sabin Vaccine Institute

Ekaterina Vert-Wong, Vice President, Portfolio & Alliance Management, Sabin Vaccine Institute

Ekaterina Vert-Wong is the vice president of Research & Development Operations at the Sabin Vaccine Institute. In this role, she leads operational, organizational and alliance management functions. Since joining Sabin in 2021, she oversees R&D programs planning and execution and leads the development teams in the implementation of efficient operations and cost-effective systems to meet current and future needs of the organization. Ekaterina fosters Sabin’s internal and external collaborations to move vaccine development milestones forward, secure funding, and implement long-term pipeline strategies, internally and externally via effective alliance management. Ekaterina brings excellent knowledge of global vaccines R&D practices, proven record of success in leading medical innovation, including execution of all clinical phases and design of global regulatory strategies. Prior to joining Sabin, Ekaterina lead departments within innovative and dynamic research organizations, focusing on the development and testing of vaccines and biologics. She has more than 20 years of experience in product development, including development and licensure of BioThrax® for post-exposure prophylaxis and pre-exposure use in special populations at Emergent BioSolutions and development of anti-pertussis antibodies for passive vaccination applications under the alliance with the Gates Foundation she created while at Synthetic Biologics. Ekaterina received her graduate degree in Management from Dartmouth College and a graduate degree in Biochemistry from the Weizmann Institute of Science in Israel. Ekaterina is a dedicated medical innovator committed to bringing vaccines with high societal impacts to patients in need via ethical and equitable research pathways.


Day 3 - November 30 @ 08:40

Keynote Panel: Beyond Borders: Collaborating for success in developing vaccines for emerging infectious diseases

  • Challenges around stock piling vaccines that are not yet licensed – 
    • need for (relatively small) stockpiles of “vialed and quality-tested vaccines that are ready to be clinically tested in populations as soon as the next outbreak strikes”.
    • Is stockpiling the victim of market failure?
    • Funding mechanisms decoupled from the market
  • Aligning programmatic interests during outbreaks and “peace times
    • Experiences getting Sudan Ebola vaccines to Uganda
  • Alternative regulatory pathways and accelerated development
  • Aligning interests & objectives of international funding partners
last published: 02/Jan/24 12:15 GMT

back to speakers